Identify treatable tumour tissue
DNA+RNA biomarkers

TruSight Oncology 500

Trusight oncology 500

  • DNA + RNA biomarkers in formalin fixed, paraffin embedded tumour tissue
  • Designed by Illumina
  • Analytical validation, clinical validation and testing at the Peter MacCallum Cancer Centre, Melbourne
  • 523 genes:

- single nucleotide variations (SNVs)

- insertions/deletions (indels)

- copy number alterations (CNAs)

- fusions

  • Tumour agnostic biomarkers:

- Tumour Mutation Burden (TMB)

- MSI status

- NTRK 1-3

  • Published quality metrics:

- robust assay with low failure rate (<1%)

- high sensitivity across range of mutant allele frequencies

- very high specificity

  • Clinical reporting of all FDA/NCCN approved biomarkers
  • Clinical trial availability reported in each case
  • MDM review of all cases with option for referring clinician to participate

Insurance cover

Order a test

For patients:

  • Contact your Doctor to arrange testing


For clinicians:

  • Download and complete the test requisition form. Please provide patient contact details (email and mobile number)
  • Scan and email to richard@sequenca.nz with a copy of the histology report
  • Sequenca Genetics will obtain slides and tissue blocks, select relevant block, and send to PeterMac for testing



Got a question?

Submitting Form...

The server encountered an error.

Form received.